5/8/2020 6:06:08 AM
Pluristem: FDA Clears IND Application For Phase II COVID-19 Study Of PLX Cells
5/5/2020 10:04:09 AM
Pluristem Announces Pricing Of Registered Direct Offering For $15 Mln
4/13/2020 6:12:48 AM
Pluristem Says Cleared By FDA To Proceed With Treatment In U.S. Under CTAP
12/17/2019 7:08:14 AM
Pluristem Enrolls 75% Of 246 Patients Planned For Phase III Study Of PLX-PAD
7/17/2019 7:08:26 AM
Pluristem, U.S. DoD To Announce Data From Studies Testing PLX-R18
6/24/2019 7:16:51 AM
Pluristem Appoints Yaky Yanay As Sole CEO And President
6/24/2019 7:08:54 AM
Pluristem Names Yaky Yanay As Sole CEO And President; Appoints Zami Aberman As Executive Chairman
5/6/2019 7:05:29 AM
Pluristem Files Patent Application For Use Of Its Advanced Manufacturing Technology In The Cannabis Industry
1/22/2019 7:05:41 AM
Pluristem To Partner With Israeli Ministry Of Defense In The Treatment Of Burn Injuries
1/9/2019 8:11:39 AM
Pluristem Therapeutics Reports Successful Case Study In Treatment Of Buerger’s Disease Patient
1/3/2019 8:35:06 AM
Pluristem Concludes Positive Meeting With FDA On Development Plan For Acute Radiation Syndrome